Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 22, 2020

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
COVID-19 Drug Treatment
Interventions
DRUG

Sarilumab

Treatment with Sarilumab 200 mg IV x 2 doses 24 hours apart for first 5 patients. If no severe AE and no significant improvement within 48 hours, the dose will be increased for subsequent patients to 400 mg IV for the first dose and 200 mg or 400 mg IV for the second dose 24 hours later. Te second dose will be decided at the investigators discretion.

Trial Locations (2)

28031

RECRUITING

Hospital Universitario Infanta Leonor, Madrid

31008

RECRUITING

Clínica Universidad de Navarra, Universidad de Navarra, Pamplona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Hospital Universitario Infanta Leonor

OTHER

lead

Clinica Universidad de Navarra, Universidad de Navarra

OTHER